STRO-001 Biosimilar – Anti-HLA-DR antigens-associated invariant chain mAb – Research Grade

Description of STRO-001 Biosimilar - Anti-HLA-DR antigens-associated invariant chain mAb - Research Grade

Introduction

STRO-001 Biosimilar is a novel monoclonal antibody (mAb) that specifically targets the human leukocyte antigen-DR (HLA-DR) antigens-associated invariant chain (Ii). This biosimilar is a promising therapeutic agent for the treatment of various types of cancer. In this article, we will discuss the structure, activity, and potential applications of STRO-001 Biosimilar in the field of oncology.

Structure

STRO-001 Biosimilar is a recombinant humanized mAb that belongs to the IgG1 subclass. It has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of three constant domains (CH1, CH2, and CH3) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL). The variable domains of the heavy and light chains are responsible for the antigen-binding specificity of STRO-001 Biosimilar.

Activity

STRO-001 Biosimilar specifically targets the HLA-DR antigens-associated Ii, which is a chaperone protein involved in the presentation of antigens to T cells. The overexpression of Ii has been observed in various types of cancer, including B-cell lymphomas, multiple myeloma, and solid tumors. By targeting Ii, STRO-001 Biosimilar inhibits the presentation of tumor antigens to T cells, thereby preventing the activation of an immune response against the cancer cells.

In addition, STRO-001 Biosimilar also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These mechanisms of action further enhance the anti-tumor activity of STRO-001 Biosimilar by promoting the destruction of cancer cells.

Application

STRO-001 Biosimilar has shown promising results in preclinical studies, demonstrating its potential as a therapeutic agent for the treatment of various types of cancer. It has been shown to effectively inhibit tumor growth in animal models of B-cell lymphoma, multiple myeloma, and solid tumors. Moreover, STRO-001 Biosimilar has also shown synergistic effects when combined with other anti- cancer therapies, such as chemotherapy and targeted therapy.

Currently, STRO-001 Biosimilar is being evaluated in phase 1 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma and multiple myeloma. These trials aim to assess the safety, tolerability, and efficacy of STRO-001 Biosimilar in human subjects. If successful, STRO-001 Biosimilar could potentially become a new treatment option for patients with these types of cancer.

Conclusion

In summary, STRO-001 Biosimilar is a promising therapeutic agent that specifically targets the HLA-DR antigens-associated Ii, a protein overexpressed in various types of cancer. Its unique mechanism of action, along with its potential for synergistic effects, make it a promising candidate for the treatment of B-cell lymphoma, multiple myeloma, and solid tumors. With ongoing clinical trials, STRO-001 Biosimilar could potentially become a valuable addition to the current arsenal of anti- cancer therapies.